THE VIRGINIAN-PILOT
Copyright (c) 1994, Landmark Communications, Inc.
DATE: Tuesday, October 11, 1994 TAG: 9410110311
SECTION: FRONT PAGE: A9 EDITION: FINAL
SOURCE: ASSOCIATED PRESS
DATELINE: NEW YORK LENGTH: Short : 26 lines
Researchers using an experimental drug have for the first time slowed the progression of a type of multiple sclerosis in which unpredictable attacks leave victims increasingly disabled.
The medication, like another experimental drug discussed on Monday at the annual meeting of the American Neurological Association in San Francisco, also reduces the number of MS attacks.
The drugs are aimed at a relapsing kind of MS that affects 75,000 to 140,000 Americans. In all, 250,000 to 350,000 Americans have MS.
People with relapsing MS suffer bouts of symptoms, including fatigue, impaired vision, loss of balance and coordination, slurred speech, tremors and partial or complete paralysis. by CNB